Close
Steven Bellan

Assistant Professor

Education

Affiliations

Projects

Papers

Bellan SE, Eggo RM, Gsell PS, Kucharski AJ, Dean NE, Donohue R, Zook M, Edmunds WJ, Odhiambo F, Longini IM Jr., Brisson M, Mahon BE, Henao-Restrepo AM. (2019). An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool. Vaccine, 37(31)

Mercaldo RA, Bellan SE. (2019). Evaluation of alternative endpoints for ZIKV vaccine efficacy trials. Vaccine, 37(15)

Fox SJ, Bellan SE, Perkins TA, Johansson MA, Meyers LA. (2019). Downgrading disease transmission risk estimates using terminal importations. PLoS neglected tropical diseases, 13(6)

Kahn R, Hitchings M, Wang R, Bellan SE, Lipsitch M. (2019). Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection. American journal of epidemiology, 188(2)

Bellan SE, Champredon D, Dushoff J, Meyers LA. (2018). Couple serostatus patterns in sub-Saharan Africa illuminate the relative roles of transmission rates and sexual network characteristics in HIV epidemiology. Scientific reports, 8(1)

Shen M, Xiao Y, Rong L, Meyers LA, Bellan SE. (2018). The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco. BMC medicine, 16(1)

Kahn R, Hitchings M, Bellan S, Lipsitch M. (2018). Impact of stochastically generated heterogeneity in hazard rates on individually randomized vaccine efficacy trials. Clinical trials (London, England), 15(2)

Hitchings MDT, Lipsitch M, Wang R, Bellan SE. (2018). Competing Effects of Indirect Protection and Clustering on the Power of Cluster-Randomized Controlled Vaccine Trials. American journal of epidemiology, 187(8)

Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M. (2017). Simulations for designing and interpreting intervention trials in infectious diseases. BMC medicine, 15(1)

Shen M, Xiao Y, Rong L, Meyers LA, Bellan SE. (2017). Early antiretroviral therapy and potent second-line drugs could decrease HIV incidence of drug resistance. Proceedings. Biological sciences, 284(1857)

Means AR, Risher KA, Ujeneza EL, Maposa I, Nondi J, Bellan SE. (2017). Correction: Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database. PLoS One, 12(1)

Castro LA, Fox SJ, Chen X, Liu K, Bellan SE, Dimitrov NB, Galvani AP, Meyers LA. (2017). Assessing real-time Zika risk in the United States. BMC infectious diseases, 17(1)

Means AR, Risher KA, Ujeneza EL, Maposa I, Nondi J, Bellan SE. (2016). Impact of Age and Sex on CD4+ Cell Count Trajectories following Treatment Initiation: An Analysis of the Tanzanian HIV Treatment Database. PLoS One, 11(10)

Sempa JB, Dushoff J, Daniels MJ, Castelnuovo B, Kiragga AN, Nieuwoudt M, Bellan SE. (2016). Reevaluating Cumulative HIV-1 Viral Load as a Prognostic Predictor: Predicting Opportunistic Infection Incidence and Mortality in a Ugandan Cohort. American journal of epidemiology, 184(1)

Bellan SE, Pulliam JR, Pearson CA, Champredon D, Fox SJ, Skrip L, Galvani AP, Gambhir M, Lopman BA, Porco TC, Meyers LA, Dushoff J. (2015). Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. The Lancet. Infectious diseases, 15(6)